Spur Therapeutics released positive Phase 1/2 trial data for FLT201, a gene therapy for Gaucher disease type 1. The therapy showed significant improvements in lyso-Gb1, a key disease marker, and maintained or improved blood counts, organ volume, and bone marrow burden after a single infusion. FLT201 also demonstrated a favorable safety profile.
This advancement is crucial for Gaucher disease patients who often experience persistent, debilitating symptoms despite existing treatments like enzyme replacement therapy (ERT) or substrate reduction therapy (SRT). FLT201 offers the potential for a one-time treatment that could provide more effective and sustained relief from these symptoms, freeing patients from the burden of lifelong therapy. The positive safety profile observed so far further strengthens the therapy’s potential to improve patients’ quality of life significantly.
The Phase 1/2 GALILEO-1 trial involved six patients with Gaucher disease type 1, previously treated with ERT or SRT. Patients who received a single, low dose of FLT201 showed reductions in lyso-Gb1 ranging from 33% to 96%. Furthermore, they maintained normal hemoglobin levels and saw improvements or stabilization in platelet counts, spleen and liver volume, and bone marrow burden over a year after discontinuing prior treatments. Importantly, no serious adverse events or infusion reactions were observed. Spur Therapeutics has aligned with the FDA on a Phase 3 trial design, anticipating accelerated approval based on lyso-Gb1 reduction and full approval based on hemoglobin levels.
The promising Phase 1/2 results and FDA alignment suggest a positive outlook for FLT201. A successful Phase 3 trial could lead to a transformative treatment option for Gaucher disease, offering a one-time solution that significantly improves patient outcomes and reduces the need for continuous treatment. This development could reshape the Gaucher disease treatment landscape, offering a new standard of care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
